Co-infections and Related Conditions (CRC)
This study aimed to investigate the safety and efficacy of TG4040 (MVA-HCV), a hepatitis C virus (HCV) therapeutic vaccine for the treatment of HCV in people who have already been diagnosed and treated and have experienced a relapse. The study also aimed determine whether the vaccine can decrease HCV viral load.
TG4040 has not been tested on people and is considered an investigational drug, meaning Health Canada, the United States Food and Drug Administration (FDA) and other regulatory agencies have not approved it for general use.
This study was terminated.